FDA Brief

Warning letters Drugs

FDA warning letter to

Novid Group, Inc.

High riskIssued Dec 7, 2023Posted Dec 12, 2023Center for Drug Evaluation and Research | CDER

FDA told Novid Group its OTC nasal spray, novid NASAL SPRAY, is an unapproved new drug and misbranded.

What happened

FDA reviewed the company's website at https://getnovid.com/ on October 12, 2023, where the product is offered for sale. FDA found the spray marketed as a combination antihistamine and nasal decongestant, with labeled active ingredients sodium chloride and organic fulvic acids, which are not permitted under the OTC cold, cough and allergy monograph (FDA's rulebook for such products). FDA also found website claims that the spray protects against catching colds or viral infections and boosts immune activity.

What FDA found

  1. The spray is a new drug sold without an FDA-approved application.

    Section 505(a), 21 U.S.C. 355(a)
  2. Its active ingredients, sodium chloride and organic fulvic acids, are not allowed for this kind of OTC product under the cold, cough and allergy monograph.

    Section 505G, 21 U.S.C. 355h
  3. Labeling claims that it protects people from catching colds or viral infections are not permitted under that monograph.

    Section 505G, 21 U.S.C. 355h; 21 CFR 201.128
  4. Claims that it reduces inflammation and enhances immune cell activity are not permitted under that monograph.

    Section 505G, 21 U.S.C. 355h
  5. The product is misbranded because it does not meet the requirements for marketing without an approved application.

    Section 502(ee), 21 U.S.C. 352(ee)
  6. Shipping the product across state lines is prohibited.

    Sections 301(a) and 301(d), 21 U.S.C. 331(a) and 331(d)

What FDA wants

FDA asks the company to write within 15 working days describing the specific steps taken to correct the violations, with an explanation of how recurrence will be prevented and copies of related documents. If corrections cannot be finished in that time, the company must say why and give a completion date; the response goes by email to FDAAdvisory@fda.hhs.gov.

Who should pay attention

  • retailers and online marketplaces that list this spray
  • brands selling OTC nasal sprays with non-monograph ingredients
  • companies making infection-prevention or immune-boosting claims for consumer health products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Bella’s Nutri Shop Inc.

    Bella’s Nutri Shop sells “Tawon Liar” as an unapproved drug with hidden dexamethasone, tapentadol, and meloxicam.

    High risk
  4. Phuoc Loc Tho Herbals, Inc.

    FDA warned Phuoc Loc Tho Herbals that its herbal products are unapproved new drugs marketed with disease claims.

    High risk